Atossa Therapeutics develops oral medicines for breast cancer and other breast conditions, based in Seattle. ATOS reports earnings on Wed, Nov 11, 2026.
Prices, price targets and earnings estimates for ATOS are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in ATOS in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ATOS is in one of them and how their past ATOS trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Atossa Therapeutics
Atossa Therapeutics is a biopharmaceutical company based in Seattle, Washington, that develops medicines for breast cancer and other breast conditions. Its main product in development is an oral drug called (Z)-endoxifen, which is still being tested in clinical studies. The drug is being studied for women with breast cancer, including for treating early breast cancer and for lowering breast density. The company is also exploring whether the drug could help with some rare diseases.
